Literature DB >> 17085351

Ligustrazine alleviates acute lung injury in a rat model of acute necrotizing pancreatitis.

Jian-Xin Zhang1, Sheng-Chun Dang.   

Abstract

BACKGROUND: Acute necrotizing pancreatitis leads to a systemic inflammatory response characterized by widespread leukocyte activation and, as a consequence, distant lung injury. The aim of this study was to evaluate the effect of ligustrazine, extracted from Ligusticum wallichii a traditional Chinese medicine, on lung injury in a rat model of acute necrotizing pancreatitis (ANP).
METHODS: A total of 192 rats were randomly divided into three groups: control (C group); ANP without treatment (P group); and ANP treated with ligustrazine (T group). Each group was further divided into 0.5, 2, 6 and 12 hours subgroups. All rats were anesthetized with an intraperitoneal injection of sodium pentobarbital. Sodium taurocholate was infused through the pancreatic membrane to induce ANP. For the T group, sodium taurocholate was infused as above, then 0.6% ligustrazine was administered via the femoral vein. The effects of ligustrazine on the severity of lung injury were assessed by lung wet/dry weight ratio, myeloperoxidase (MPO) activity and histopathological changes. Pulmonary blood flow was determined by the radioactive microsphere technique (RMT).
RESULTS: The blood flow in the P group was significantly lower than that of the C group, while the blood flow in the T group was significantly higher than that of the P group but showed no significant difference from the C group. Compared with C group, the lung wet/dry ratios in both the P and T groups were significantly increased, but there was no significant difference between them. The MPO activity in the P group was greatly increased over that of the C group. In the T group, although the MPO activity was also higher than in the C group, it much less increased than in the P group. Moreover, the difference between P and T groups was significant after 0.5 to 12 hours. After induction of the ANP model, the pancreas showed mild edema and congestion; the longer the time, the more severe this became. The pulmonary pathological changes were aggravated significantly in the P group. Histopathological scores were higher in the P group than in the C group throughout the experimental course. Histopathological scores in the T group were lower than those in the P group at 6 and 12 hours.
CONCLUSIONS: Microcirculatory disorder is an important factor of lung injury in ANP. Ligustrazine can ameliorate microcirculatory disorder and alleviate the damage to the lung.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17085351

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  5 in total

1.  Clodronate-containing liposomes attenuate lung injury in rats with severe acute pancreatitis.

Authors:  Sheng-chun Dang; De-li Jiang; Min Chen; Di Li; Jian-xin Zhang
Journal:  J Zhejiang Univ Sci B       Date:  2010-11       Impact factor: 3.066

2.  Are gastric mucosal macrophages responsible for gastric injury in acute pancreatitis?

Authors:  Sheng-Chun Dang; Hao Wang; Jian-Xin Zhang; Lei Cui; De-Li Jiang; Rong-Fang Chen; Jian-Guo Qu; Xiang-Qian Shen; Min Chen; Min Gu
Journal:  World J Gastroenterol       Date:  2015-03-07       Impact factor: 5.742

3.  IRF5 regulates lung macrophages M2 polarization during severe acute pancreatitis in vitro.

Authors:  Kang Sun; Song-Bing He; Jian-Guo Qu; Sheng-Chun Dang; Ji-Xiang Chen; Ai-Hua Gong; Rong Xie; Jian-Xin Zhang
Journal:  World J Gastroenterol       Date:  2016-11-14       Impact factor: 5.742

4.  Dynamic Changes of Soluble Fas and IL-2/IL-10 in serum and Fas Expression in Lung in the Rats of Acute Necrotizing Pancreatitis.

Authors:  Jian Xin Zhang; Jiang Tao Yin; Lei Cui; Sheng Chun Dang
Journal:  Gastroenterology Res       Date:  2008-11-20

Review 5.  Phytoceuticals in Acute Pancreatitis: Targeting the Balance between Apoptosis and Necrosis.

Authors:  Laura Gaman; Dorin Dragos; Adelina Vlad; Georgiana Catalina Robu; Mugurel Petrinel Radoi; Laura Stroica; Mihaela Badea; Marilena Gilca
Journal:  Evid Based Complement Alternat Med       Date:  2018-03-04       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.